These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 21781307)

  • 1. Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.
    Stuckey A; Fischer A; Miller DH; Hillenmeyer S; Kim KK; Ritz A; Singh RK; Raphael BJ; Brard L; Brodsky AS
    BMC Cancer; 2011 Jul; 11():308. PubMed ID: 21781307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model.
    Moore RG; Lange TS; Robinson K; Kim KK; Uzun A; Horan TC; Kawar N; Yano N; Chu SR; Mao Q; Brard L; DePaepe ME; Padbury JF; Arnold LA; Brodsky A; Shen TL; Singh RK
    PLoS One; 2012; 7(4):e34443. PubMed ID: 22509304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines.
    Brard L; Lange TS; Robison K; Kim KK; Ara T; McCallum MM; Arnold LA; Moore RG; Singh RK
    Gynecol Oncol; 2011 Nov; 123(2):370-8. PubMed ID: 21803404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers.
    Yokoyama Y; Xin B; Shigeto T; Mizunuma H
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1219-28. PubMed ID: 21681689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo effects of rosiglitazone in a human neuroblastoma xenograft.
    Cellai I; Petrangolini G; Tortoreto M; Pratesi G; Luciani P; Deledda C; Benvenuti S; Ricordati C; Gelmini S; Ceni E; Galli A; Balzi M; Faraoni P; Serio M; Peri A
    Br J Cancer; 2010 Feb; 102(4):685-92. PubMed ID: 20068562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
    Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
    Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-derived ovarian cancer xenografts re-growing after a cisplatinum treatment are less responsive to a second drug re-challenge: a new experimental setting to study response to therapy.
    Ricci F; Fratelli M; Guffanti F; Porcu L; Spriano F; Dell'Anna T; Fruscio R; Damia G
    Oncotarget; 2017 Jan; 8(5):7441-7451. PubMed ID: 26910918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Zeller C; Dai W; Steele NL; Siddiq A; Walley AJ; Wilhelm-Benartzi CS; Rizzo S; van der Zee A; Plumb JA; Brown R
    Oncogene; 2012 Oct; 31(42):4567-76. PubMed ID: 22249249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
    Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
    Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies.
    Faratian D; Zweemer AJ; Nagumo Y; Sims AH; Muir M; Dodds M; Mullen P; Um I; Kay C; Hasmann M; Harrison DJ; Langdon SP
    Clin Cancer Res; 2011 Jul; 17(13):4451-61. PubMed ID: 21571868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition.
    Dong YW; Wang XP; Wu K
    World J Gastroenterol; 2009 Jan; 15(4):441-8. PubMed ID: 19152448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
    Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
    Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NCX-4040, a nitric oxide-releasing aspirin, sensitizes drug-resistant human ovarian xenograft tumors to cisplatin by depletion of cellular thiols.
    Bratasz A; Selvendiran K; Wasowicz T; Bobko A; Khramtsov VV; Ignarro LJ; Kuppusamy P
    J Transl Med; 2008 Feb; 6():9. PubMed ID: 18302761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of PPARĪ³ agonistrosiglitazone on human retinoblastoma cell in vitro and in vivo.
    Cao X; He L; Li Y
    Int J Clin Exp Pathol; 2015; 8(10):12549-56. PubMed ID: 26722443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
    Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
    Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer.
    Li N; Sun C; Zhou B; Xing H; Ma D; Chen G; Weng D
    PLoS One; 2014; 9(7):e100314. PubMed ID: 24999622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1.
    Liu Y; Niu Z; Lin X; Tian Y
    Cancer Gene Ther; 2017 May; 24(5):208-214. PubMed ID: 28281524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.